We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for...
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening...
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el...
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.1 | -37.037037037 | 2.97 | 4.24 | 1.81 | 2855030 | 2.97774257 | CS |
4 | -2.079 | -52.6462395543 | 3.949 | 5.47 | 1.62 | 6740949 | 2.59706337 | CS |
12 | -3.93 | -67.7586206897 | 5.8 | 6.039 | 1.62 | 2366213 | 2.76623732 | CS |
26 | -17.13 | -90.1578947368 | 19 | 23.9 | 1.62 | 1238150 | 3.94007219 | CS |
52 | -26.43 | -93.3922261484 | 28.3 | 44 | 1.62 | 748677 | 7.95665355 | CS |
156 | -55.23 | -96.7250437828 | 57.1 | 450 | 1.62 | 1822940 | 140.45262438 | CS |
260 | -98.13 | -98.13 | 100 | 450 | 1.62 | 1779730 | 138.08936297 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions